Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cancer Genetics Launches New Genetic Test for Cervical Cancer Management

Published: Wednesday, July 24, 2013
Last Updated: Wednesday, July 24, 2013
Bookmark and Share
A published research study highlights the relevance of FHACT™ in screening women with high risk of cervical cancer.

Cancer Genetics, Inc. launched its proprietary cervical cancer test and is marketing the molecular product globally through its network of distribution partners. Cervical cancer is the second most common cancer in women worldwide, with 500,000 new cases annually and almost 80% of cases occurring in developing countries.

CGI’s FISH-based HPV-Associated Cancer Test (FHACT™) uses a unique combination of genetic markers to detect genetic abnormalities located at 3q, 5p, 20q and chromosome 7. A recent study concluded that these four biomarkers are associated with the severity of cervical lesions. The findings of the study, published in the July issue of Gynecologic Oncology,, support the use of FHACT™ as an aid in the screening of women with HPV-positive abnormal cervical lesions. By identifying lesions that will progress to a higher grade versus those that will regress, FHACT™ can allow for a better triage of patients before referral for colposcopy and consequently reduce the associated healthcare burden.

The test can be performed directly on Pap smear or liquid based-cytology and does not require any resampling. It is therefore an ideal fit in countries where women have reduced access to routine screening. “We think that FHACT™ will be a new tool to help identify women with high risk of progressing to cervical cancer,” says Dr. Q. Annie Hasan, Ph.D., F.N.A.Sc., Head of Department and Senior Consultant, Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India. “This is particularly important in India due to the rising incidence of cervical cancer caused by difficulty in implementation of cervical screening programs, which require repeated evaluation in large number of women.” In partnership with its distributors and collaborators, CGI will conduct workshops in India and Mexico to accelerate adoption of FHACT™ amongst the clinical community.

In industrialized countries, it is estimated that about one million women undergo colposcopy procedures each year, while only 3,700 cancer cases are actually diagnosed. The Company expects FHACT™ to aid in lowering healthcare costs and reducing the number of unwarranted colposcopies by providing genomic information of the lesion not available until now. CGI plans to make FHACT™ available in the U.S. later this year and will be working closely with several laboratories and hospitals to implement an early adoption of the test.

The design and development of FHACT™ was supported in part by a Small Business Innovation Research (SBIR) grant. In addition to cervical cancer, FHACT™ is applicable to other HPV-associated cancers. CGI is currently conducting ongoing validations with key thought leaders for head and neck cancer and anal cancer. Results from these studies are expected to be available by year end.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Genetics, Icon Partner
Cancer Genetics has partnered with Icon's Laboratory Services group to provide a range of services.
Wednesday, July 08, 2015
Cancer Genetics Inc. and Columbia University Researchers Collaborate
Collaboration aims to identify genomic signatures, biomarkers and novel treatments for MDS and AML.
Tuesday, October 14, 2014
Cancer Genetics, Roche Expand Agreement
Companies expand molecular diagnostic cancer testing in Central America and the Caribbean.
Tuesday, February 11, 2014
Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock
Cancer Genetics, Inc. announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share.
Monday, April 08, 2013
CGI and Aptiv Solutions Form Strategic Partnership Focused on Creating More Effective Clinical Trials in Oncology
Partnership to help biotechnology and pharmaceutical companies bring next generation oncology therapeutics to market in a more targeted and effective manner.
Saturday, March 26, 2011
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos